Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02278055 · ClinicalTrials.gov registry record · Phase 2
Non-Randomized Trial Assessing Pain Efficacy With Radium-223 in Symptomatic Metastatic Castration-Resistant Prostate Cancer
A Phase 2 study of Pain and Metastatic Prostate Cancer, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 29
- Enrollment target
- 3
- Study locations
NCT02278055: Completed Phase 2 study of Pain and Metastatic Prostate Cancer, sponsored by Memorial Sloan Kettering Cancer Center.
NCT02278055 is a Phase 2 study of Pain and Metastatic Prostate Cancer that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 29 participants, below the 304-participant average among 374 other Pain trials with a reported enrollment target (90% lower). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02278055, a Phase 2 study of Pain and Metastatic Prostate Cancer, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 29 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to find out if Radium-223 is effective in reducing cancer pain within 12 weeks of treatment. In order to see if Radium-223 is effective, the patient's level of pain will be followed throughout the study.
Primary Outcome
Defined as a 30% decline in the Brief Pain Inventory/BPI worse pain item from baseline to week 8, with a confirmed reduction at week 12 without an escalation of the subject's pain regimen from Step 1 to Step 2 or Step 2 to Step 3 of the WHO analgesic ladder.) The baseline BPI worst pain score average will be based on the worst pain scores completed by the participant in the 7 consecutive pretreatment days. A minimum of 4 days of pain scores must be completed by the participant in the 7 day windo
Conditions Studied
Interventions
- DRUG Radium-223
Study Locations (3)
New York
- Memorial Sloan Kettering Cancer Center - New York
- New York Presbyterian Hospital-Weill Medical College of Cornell University - New York
North Carolina
- University of North Carolina - Chapel Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2014-10-08 |
| Est. Completion | 2022-02-02 |
| Phase | Phase 2 |
What the finished NCT02278055 record still lists
NCT02278055 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 29 participants, a relatively small participant target, below the 304-participant average among 374 other Pain trials with a reported enrollment target (90% lower).
The record links to 2 conditions, with Pain appearing as the primary indexed condition, and to 1 intervention - of which Radium-223 is the first listed.
NCT02278055 reports a single indexed study location in New York, North Carolina.
Frequently Asked Questions
What is clinical trial NCT02278055 about?
NCT02278055 is a clinical study titled "Non-Randomized Trial Assessing Pain Efficacy With Radium-223 in Symptomatic Metastatic Castration-Resistant Prostate Cancer". The purpose of this study is to find out if Radium-223 is effective in reducing cancer pain within 12 weeks of treatment. In order to see if Radium-223 is effective, the patient's level of pain will be followed throughout the study.
What is the current status of trial NCT02278055?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 29 participants. The study started on 2014-10-08. Estimated completion is 2022-02-02.
What conditions does trial NCT02278055 study?
This clinical trial studies the following conditions: Pain, Metastatic Prostate Cancer.
What interventions are being tested in trial NCT02278055?
The interventions under investigation include: Radium-223 (DRUG).
Who is sponsoring clinical trial NCT02278055?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02278055 being conducted?
This trial has 3 study locations across New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pain
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02278055's enrollment target sits among peer trials
29 316th of 374 higher than 58 of 374 other Pain trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pain trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Pain Alleviation With Testosterone in Opioid-Induced Hypogonadism
RECRUITING · Phase 2
-
Cannabidiol and Older Adult Cannabis Users
RECRUITING · Phase 2
-
Mechanisms of Cannabidiol in Persons With MS: the Role of Sleep and Pain Phenotype
RECRUITING · Phase 2
-
Neural Correlates of Hypoalgesia Driven by Observation
RECRUITING · Phase 2
-
Cannabis for Palliative Care in Cancer
RECRUITING · Phase 2
-
Pain After Buffered Vs Non Buffered Articaine
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02429557 · 29 participants · Phase 1
Hemodynamic Mechanisms of Abdominal Compression in the Treatment of Orthostatic Hypotension in Autonomic Failure
- NCT02568878 · 29 participants · Phase 3
Creatine for Depressed Male and Female Methamphetamine Users
- NCT03014401 · 29 participants · NA
The Effect of Adipose-Derived Stem Cells for Knee Osteoarthritis
- NCT03128996 · 29 participants · Phase 1
Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI